title: Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
abstract: The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in patients receiving antiplatelet agents, oral anticoagulants and statins. Based on clinical evidence supporting genetic testing in the management of cardiovascular diseases using these drug classes, this short review presents clinical guidance regarding current pharmacogenetics implementation in routine medical practice.
authors.affiliation: Service de pharmacologie, laboratoire de pharmacologie-toxicologie et pharmacogénétique, centre hospitalier universitaire, 76031 Rouen, France; Inserm unité 1096, pharmacologie des dysfonctionnements endothéliaux et myocardiques, faculté de médecine et de pharmacie, université de Rouen, 76000 Rouen, France. Electronic address: fabien.lamoureux@chu-rouen.fr.
authors.forename: Fabien
authors.initials: F
authors.lastname: Lamoureux
authors.affiliation: Service de pharmacologie, laboratoire de pharmacologie-toxicologie et pharmacogénétique, centre hospitalier universitaire, 76031 Rouen, France; Inserm unité 1096, pharmacologie des dysfonctionnements endothéliaux et myocardiques, faculté de médecine et de pharmacie, université de Rouen, 76000 Rouen, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Duflot
mesh_terms: D000925:Anticoagulants / Q000493:pharmacokinetics; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics*; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000493:pharmacokinetics; D027381:Liver-Specific Organic Anion Transporter 1 / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D064417:Vitamin K Epoxide Reductases / Q000235:genetics*
chemical_list: D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; C503999:SLCO1B1 protein, human; D065729:Cytochrome P-450 CYP2C9; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases
keywords: Cardiovascular drugs; Clinical implementation; Pharmacogenetics; Pharmacogenomics